Clinical Trial: Trial of the Efficacy and Safety of Use of Drug Product Reamberin(R) for Pathogenetic Therapy of Viral Enteric Infection in Children Aged 1-6 Years Old

U.S., July 16 -- ClinicalTrials.gov registry received information related to the study (NCT07066540) titled 'Trial of the Efficacy and Safety of Use of Drug Product Reamberin(R) for Pathogenetic Therapy of Viral Enteric Infection in Children Aged 1-6 Years Old' on May 13.

Brief Summary: To assess the efficacy and safety of use of drug product Reamberin(R) solution for infusion, 1.5 % (Scientific Technological Pharmaceutical Firm "POLYSAN") for pathogenetic therapy of viral enteric infection in children aged 1-6 years old in routine clinical practice. Trial population: children of both sexes at the age of 1-6 years old inclusive with viral enteric infection.

Study Start Date: Aug. 01, 2024

Study Type: OBSERVATIONAL

Condition: Viral Ente...